1,088 results match your criteria: "and Children's Hospital Colorado[Affiliation]"

Racial/ethnic differences are associated with the symptoms and conditions of post-acute sequelae SARS-CoV-2 infection (PASC) in adults. These differences may exist among children and warrant further exploration. We conducted a retrospective cohort study with difference-in-differences analyzes to assess these differences in children and adolescents under the age of 21.

View Article and Find Full Text PDF

Objective: Although studies have examined changes in C-reactive protein (CRP) during pulmonary exacerbations (PEX) in people with cystic fibrosis (PwCF), few have evaluated CRP profiles across age groups. Here, we characterize age-related CRP responses to PEX treatment.

Methods: We measured CRP concentrations at the beginning and end of intravenous (IV) antibiotic therapy for PEX in 100 pediatric and 147 adult PwCF at 10 US CF Centers.

View Article and Find Full Text PDF

Digital Health for Asthma Management: Electronic Medication Monitoring for Adherence as a Case Example.

J Allergy Clin Immunol Pract

January 2025

Breathing Institute, Children's Hospital Colorado, Department of Pediatrics, Pediatric Pulmonary and Sleep Medicine Section, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO. Electronic address:

Digital health is an umbrella term for components of healthcare utilizing computer platforms, software, connectivity and sensors to augment the recording, documentation and communication of clinical information. The functions of digital health may be viewed in three domains: 1) the repository for patient information, 2) monitoring devices and 3) communication tools. Monitoring devices have provided robust information as diagnostic and prognostic tools in office and hospital settings.

View Article and Find Full Text PDF

Background: Pediatric respiratory syncytial virus (RSV)-related acute lower respiratory tract infection (LRTI) commonly requires hospitalization. The Clinical Progression Scale Pediatrics (CPS-Ped) measures level of respiratory support and degree of hypoxia across a range of disease severity, but it has not been applied in infants hospitalized with severe RSV-LRTI.

Methods: We analyzed data from a prospective surveillance registry of infants hospitalized for RSV-related complications across 39 U.

View Article and Find Full Text PDF

Congenital pulmonary airway malformations (CPAMs) are cystic lung lesions often detected prenatally. Resection is often recommended for potential recurrent infections and malignancy. This report describes a case of a 14-year-old female patient who presented with abdominal pain.

View Article and Find Full Text PDF

Association Between Early Immunosuppression Center Variability and One-Year Outcomes After Pediatric Liver Transplant.

Pediatr Transplant

February 2025

Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.

Background: Despite the existence of institutional protocols, liver transplant centers often have variability in early immunosuppression practices. We aimed to measure within-center variability in early immunosuppression after pediatric liver transplant (LT) and examine its association with one-year outcomes.

Methods: We analyzed pediatric LTs from 2013 to 2018 in the United Network for Organ Sharing registry, with data aggregated by center.

View Article and Find Full Text PDF

Oral Delivery of miR146a Conjugated to Cerium Oxide Nanoparticles Improves an Established T Cell-Mediated Experimental Colitis in Mice.

Pharmaceutics

December 2024

Laboratory for Fetal and Regenerative Biology, Department of Surgery, University of Arizona Tucson College of Medicine, Banner Children's at Diamond Children's Medical Center, 1656 E Mabel St, Rm 230, Tucson, AZ 85721, USA.

Dysregulated inflammation and oxidative stress are strongly implicated in the pathogenesis of inflammatory bowel disease. We have developed a novel therapeutic that targets inflammation and oxidative stress. It is comprised of microRNA-146a (miR146a)-loaded cerium oxide nanoparticles (CNPs) (CNP-miR146a).

View Article and Find Full Text PDF

Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.

Lancet Respir Med

December 2024

Population Policy and Practice Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. Electronic address:

Article Synopsis
  • Vanzacaftor-tezacaftor-deutivacaftor is a new CFTR modulator showing safety and effectiveness in phase 2 trials for adults with cystic fibrosis, leading to a study evaluating its use in children aged 6-11.
  • This phase 3 trial, called RIDGELINE, involved participants from 33 clinical sites across eight countries, focusing on children with specific CFTR variants and stable health conditions.
  • The study aimed to assess the drug's safety, tolerability, and efficacy over 24 weeks, with primary outcomes evaluated through various health metrics and participant feedback.
View Article and Find Full Text PDF

Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment.

J Cyst Fibros

January 2025

Cystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Hospital, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA.

Background: Highly effective CFTR modulators improve CFTR function and lead to dramatic improvements in health outcomes in many people with cystic fibrosis (pwCF). The relationship between measures of CFTR function, such as sweat chloride concentration, and clinical outcomes in pwCF treated with CFTR modulators is poorly defined. We conducted analyses to better understand the relationships between sweat chloride and CFTR function in vitro, and between sweat chloride and clinical outcomes following CFTR modulator treatment.

View Article and Find Full Text PDF

Background: The impact of pre-infection vaccination on the risk of long COVID remains unclear in the pediatric population. We aim to assess the effectiveness of BNT162b2 on long COVID risks with various strains of the SARS-CoV-2 virus in children and adolescents, using comparative effectiveness methods. We further explore if such pre-infection vaccination can mitigate the risk of long COVID beyond its established protective benefits against SARS-CoV-2 infection using causal mediation analysis.

View Article and Find Full Text PDF

Reply to: Accurate Determinants of Outcome in ALL.

J Clin Oncol

December 2024

Ti-Cheng Chang, PhD, Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN; Wenan Chen, PhD, Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN, Division of Computational Biology, Mayo Clinic, Rochester, MN; Chunxu Qu, PhD, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; Zhongshan Cheng, PhD, Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN; Abdelrahman Elsayed, PhD and Stanley B. Pounds, PhD, Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN; Mary Shago, PhD, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; Karen R. Rabin, MD, PhD, Department of Pediatrics, Baylor College of Medicine, Houston, TX; Elizabeth A. Raetz, MD, Department of Pediatrics, Perlmutter Cancer Center, NYU Langone Hospital, New York, NY; Meenakshi Devidas, PhD, Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN; Cheng Cheng, PhD, Department of Biostatistics, St Jude Children's Research Hospital, Memphis, TN; Anne Angiolillo, MD, Children's National Medical Center, Washington, DC; Pradyuamma Baviskar, PhD, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; Michael Borowitz, MD, Department of Pathology, Johns Hopkins University, Baltimore, MD; Michael J. Burke, MD, Division of Pediatric Hematology-Oncology, Medical College of Wisconsin, Milwaukee, WI; Andrew Carroll, PhD, Department of Genetics, University of Alabama at Birmingham, Birmingham, AL; William L. Carroll, MD, Department of Pediatrics, Perlmutter Cancer Center, NYU Langone Hospital, New York, NY; I-Ming Chen, DVM and Richard Harvey, PhD, Department of Pathology, University of New Mexico, Albuquerque, NM; Nyla Heerema, PhD, The Ohio State University, Columbus, OH; Ilaria Iacobucci, PhD, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; Jeremy R. Wang, PhD, Department of Genetics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; Sima Jeha, MD, Department of Oncology, St Jude Children's Research Hospital, Memphis, TN; Eric Larsen, MD, Department of Pediatrics, Maine Children's Cancer Program, Scarborough, ME; Leonard Mattano, MD, HARP Pharma Consulting, Mystic, CT; Kelly Maloney, MD, Department of Pediatrics and Children's Hospital Colorado, University of Colorado, Aurora, CO; Ching-Hon Pui, MD, Department of Oncology, St Jude Children's Research Hospital, Memphis, TN; Nilsa C. Ramirez, MD, Institute for Genomic Medicine and Biopathology Center, Nationwide Children's Hospital, Departments of Pathology and Pediatrics, Ohio State University, Columbus, OH; Wanda Salzer, MD, Uniformed Services University, School of Medicine, Bethesda, MD; Cheryl Willman, MD, Department of Laboratory Medicine and Pathology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN; Naomi Winick, MD, Department of Pediatric Hematology Oncology and Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Brent Wood, MD, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA; Stephen P. Hunger, MD, Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia, and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Gang Wu, PhD, Center for Applied Bioinformatics, St Jude Children's Research Hospital, Memphis, TN, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; Charles G. Mullighan, MBBS, MD, Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; and Mignon L. Loh, MD, Department of Pediatrics and the Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, University of Washington, Seattle, WA.

View Article and Find Full Text PDF

Pulmonary veno-occlusive disease (PVOD) is a lethal variant of pulmonary hypertension. The degree of pulmonary arterial involvement varies. Here, we compare two PVOD patients who were transplanted at 8 years of age, whereof one is a homozygous mutation carrier.

View Article and Find Full Text PDF

As cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies including elexacaftor/tezacaftor/ivacaftor (ETI) have become widely used in eligible patients with cystic fibrosis (CF), the use of these medications in pregnant people has become a critical area of investigation. Since these medications appear generally safe to both mother and fetus when taken by pregnant people with CF, interest has pivoted to the use of ETI in CF carrier mothers to decrease morbidity and mortality from meconium ileus (MI) in fetuses with cystic fibrosis. Here we discuss three infants at our institution with ultrasound findings of MI who were exposed to prenatal ETI through CF carrier mothers for the purposes of treating MI and lowering risk of intestinal complications from this severe manifestation of CF.

View Article and Find Full Text PDF
Article Synopsis
  • The use of non-pharmaceutical interventions (NPIs) during COVID-19 led to a decrease in various respiratory illnesses but created a build-up of susceptible individuals for future outbreaks.
  • Unlike other respiratory pathogens that rebounded quickly after NPIs, Mycoplasma pneumoniae (Mp) outbreaks have been significantly delayed, with reports of delays over three years in Europe and Asia.
  • Researchers are employing mathematical models to forecast a significant Mp outbreak in the US, highlighting the impact of NPIs and decreasing immunity on the duration of epidemic delays.
View Article and Find Full Text PDF
Article Synopsis
  • Viral lower respiratory tract infection (vLRTI) significantly impacts global child health, prompting research into the host immune responses using proteomics for better understanding and diagnosis.
  • The study analyzed 1,305 proteins from tracheal aspirate and plasma of 62 critically ill children, finding 200 differentially expressed proteins that reveal key immune responses, with a robust nine-protein TA classifier showing high diagnostic accuracy (AUC of 0.96).
  • It also highlighted the limited correlation between tracheal aspirate and plasma proteins and examined how viral load and bacterial co-infections influence immune signaling pathways.
View Article and Find Full Text PDF

Background: Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory illness among young children. Human immunodeficiency virus (HIV)-exposed, uninfected (HEU) children experience a higher burden of RSV disease and have immune abnormalities that may influence their responses to live-attenuated RSV vaccines.

Methods: In a pooled analysis of clinical trials of 7 live-attenuated, intranasal RSV vaccines conducted by the IMPAACT Network among children 6 to <25 months of age with serum RSV-neutralizing titers of <1:40, the infectivity and immunogenicity of these vaccines were compared among HEU and HIV-unexposed, uninfected (HUU) children.

View Article and Find Full Text PDF

Objective: To characterize clinical, hemodynamic, imaging, and pathologic findings in children with pulmonary arterial hypertension (PAH) and variants in SRY-box transcription factor 17 (SOX17), a novel risk gene linked to heritable and congenital heart disease-associated PAH.

Study Design: We assembled a multi-institutional cohort of children with PAH and SOX17 variants enrolled in the Pediatric Pulmonary Hypertension Network (PPHNet) and other registries. Subjects were identified through exome and PAH gene panel sequencing.

View Article and Find Full Text PDF

Clinical guidelines for infant feeding among people with HIV in the U.S. were updated in 2023 to encourage providers to utilize a shared decision-making approach that includes breastfeeding/chestfeeding (B/CF) when appropriate.

View Article and Find Full Text PDF

Objective: Not much is known regarding musculoskeletal ultrasound (MSUS) practices of rheumatologists in the United States. We sought to determine the current use of MSUS among past participants of the Ultrasound School of North American Rheumatologists (USSONAR) training program and, by extension, MSUS-practicing rheumatologists and to understand barriers to its MSUS use.

Methods: An online survey was sent to 374 participants in the eight-month USSONAR blended course (Fundamentals in Musculoskeletal Ultrasound and Train the Trainer) between 2009 and 2020.

View Article and Find Full Text PDF
Article Synopsis
  • The MMPOWER-3 clinical trial initially found no overall benefit of elamipretide for adults with primary mitochondrial myopathy, but a subgroup with nuclear DNA variants showed improvement in a six-minute walk test.
  • A large portion of the trial subjects had mitochondrial DNA variants, with particular improvements noted among those possessing pathogenic variants related to mtDNA maintenance.
  • Further analyses aim to identify trends among responders to assist in designing a more targeted Phase 3 trial for those likely to benefit from elamipretide.
View Article and Find Full Text PDF

Context: Clinical balance assessments vary in reliability due to subjectivity in their scoring. A valid and objective accelerometer-based smartphone evaluation could benefit patients, clinicians, and researchers.

Objective: Our objective was to assess the validity and reliability of smartphone-based standing balance.

View Article and Find Full Text PDF

Background: Setmelanotide, a melanocortin-4 receptor (MC4R) agonist, has been shown to reduce hunger and weight in patients aged 6 years and older with proopiomelanocortin (POMC) deficiency (including biallelic variants in proprotein convertase subtilisin/kexin type 1 [PCSK1]), leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome (BBS). No approved therapies for patients younger than 6 years old currently exist. The phase 3, open-label VENTURE trial aimed to evaluate the efficacy and safety of setmelanotide in patients aged 2-5 years with POMC or LEPR deficiency or BBS.

View Article and Find Full Text PDF